Measuring health-related quality of life in diabetic peripheral neuropathy: A systematic review

Diabetes Research and Clinical Practice

Volumn 96, Issue 3, 2012, Pages 261-270

  Smith, S C ^a   Lamping, D L ^a   Maclaine, G D H ^b,c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Becton Dickinson UK Ltd   (United Kingdom)

^c EISAI CO LTD   (Japan)

Author keywords

Diabetic peripheral neuropathy; Health related quality of life; Patient reported outcome measures; Psychometric

Indexed keywords

CONCURRENT VALIDITY; CONTENT VALIDITY; CRITERION RELATED VALIDITY; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DISCRIMINANT VALIDITY; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; NEUROQOL; NORFOLK QOL DN; PERIPHERAL NEUROPATHY; PN QOL 97; PREDICTIVE VALIDITY; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SYSTEMATIC REVIEW; TEST RETEST RELIABILITY;

DIABETIC NEUROPATHIES; FEMALE; GREAT BRITAIN; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE;

EID: 84862182517     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.11.013     Document Type: Review

References (57)

1. Boulton A.J.M., Rayaz A.M., Arezzo J.C., Sosenko J.M. Diabetic somatic neuropathies. Diabetes Care 2004, 27(6):1458-1486.
2. Benbow S.J., Wallymahmed M.E., Macfarlane I.A. Diabetic peripheral neuropathy and quality of life. Q J Med 1998, 91:733-737.
3. Galer B.S., Gianas A., Jensen M.P. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123-128.
4. Gore M., Brandenburg N.A., Dukes E., Hoffman D.L., Tai K.S., Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005, 30:374-385.
5. Chyun D.A., Melkus G.D., Katten D.M., Price W.J., Davey J.A., Grey N., et al. The association of psychological factors, physical activity, neuropathy, and quality of life in type 2 diabetes. Biol Res Nurs 2006, 7(4):279-288.
6. Haanpää M., Attal N., Backonja M., Baron R., Bennett M., Bouhassira D., et al. Guidelines on neuropathic pain NeuPSIG. assessment. Pain 2011, 152:14-27.
7. Poole H.M., Murphy P., Nurmikko T.J. Development and preliminary validation of the NePIQoL: a quality-of-life measure for neuropathic pain. J Pain Symptom Manage 2009, 37(2):233-245.
8. Vinik A.I., Maser R.E., Mitchell B.D., Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
9. Food Drug Administration Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims: draft guidance 2006, Department of Health and Human Services Food and Drug Administration, Rockville, MD, US, Available at. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1629006/pdf/1477-7525-4-79.pdf.
10. National institute for health and clinical excellence. Guide to the methods of technology appraisal. Publication reference N1618 2008, NICE, London.
11. Swislocki A., Orth M., Bales M., Weisshaupt J., West C., Edrington J., et al. A randomized clinical trial of the effectiveness of photon stimulation on pain, sensation, and quality of life in patients with diabetic peripheral neuropathy. J Pain Symptom Manage 2010, 39(1):88-99.
12. Lewko J., Polityńska B., Kochanowicz J., Zarzycki W., Okruszko A., Sierakowska M., et al. Quality of life and its relationship to the degree of illness acceptance in patients with diabetes and peripheral diabetic neuropathy. Adv Med Sci 2007, 52(Suppl. 1):144-146.
13. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. KORA study group treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009, 32(8):1479-1484.
14. Viala-Danten M., Martin S., Guillemin I., Hays R.D. Evaluation of the reliability and validity of the Medical Outcomes Study sleep scale in patients with painful diabetic peripheral neuropathy during an international clinical trial. Health Qual Life Outcomes 2008, 17(6):113.
15. Yalcin B.M., Karahan T.F., Ozcelik M., Igde F.A. The effects of an emotional intelligence program on the quality of life and well-being of patients with type 2 diabetes mellitus. Diabetes Educ 2008, 34(6):1013-1024.
16. Armstrong D.G., Lavery L.A., Wrobel J.S., Vileikyte L. Quality of life in healing diabetic wounds: does the end justify the means?. J Foot Ankle Surg 2008, 47(4):278-282.
17. Van Acker K., Bouhassira D., De Bacquer D., Weiss S., Matthys K., Raemen H., et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009, 35(3):206-213.
18. Hoffman D.L., Sadosky A., Dukes E.M., Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010, 149(May (2)):194-201. [Epub 2010 March 19].
19. Baron R., Mayoral V., Leijon G., Binder A., Steigerwald I., Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009, 25(7):1663-1676.
20. Wróbel M.P., Szymborska-Kajanek A., Wystrychowski G., Biniszkiewicz T., Sieroń-Stołtny K., Sieroń A., et al. Impact of low frequency pulsed magnetic fields on pain intensity, quality of life and sleep disturbances in patients with painful diabetic polyneuropathy. Diabetes Metab 2008, 34(4 Pt 1):349-354.
21. Bowling A. Measuring disease 1995, Open University Press, Buckingham.
22. Staquet M.J., Hays R.D., Fayers P.M. Quality of life assessment in clinical trials. methods and practice 1998, Oxford University Press, Oxford.
23. Mckenna S.P. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med 2011, 9:86.
24. Terwee C.B., Jansma E.P., Riphagen I.I., de Vet H.C.W. Development of a methodological PubMed search filter for finding studies on measurement properties of measurement instruments. Qual Life Res 2009, 18(8):1115-1123.
25. Smith S.C., Cano S., Lamping D.L., Staniszewska S., Browne J., Lewsey J., et al. Patient-reported outcome measures (PROMs) for routine use in treatment centres: recommendations based on a review of the scientific evidence. Final report to the Department of Health 2005.
26. Fitzpatrick R., Davey C., Buxton M., Jones D. Evaluating patient-based outcomemeasures for use in clinical trials 1998, Southampton National Coordinating Centre for Health Technology Assessment, 1-73.
27. Patrick D., Erickson P. What constitutes quality of life? Concepts and dimensions. Clin Nutr 1988, 7(2):53-63.
28. Ettema T.P., Dröes R., de Lange J., Gideon J., Mellenbergh G.J., Ribbe M.W. A review of quality of life instruments used in dementia. Qual Life Res 2005, 14(3):675-686.
29. Lamping D., Schroter S., Kurz X., Kahn S.L.A. Evaluating outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measures of symptoms and quality of life. J Vasc Surg 2003, 37:410-419.
30. Lamping D., Schroter S., Marquis P., Marrel A., Duprat-Lomon I., Sagnier P. The community-acquired pneumonia symptom questionnaire. A new, patient-based outcome measure to evaluate symptoms in patients with community acquired pneumonia. Chest 2002, 122:920-929.
31. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality of life instruments: attributes and review criteria. Quality of Life Research, 2002; 11, 193-205.
32. Vinik E.J., Hayes R.P., Oglesby A., Bastyr E., Barlow P., Ford-Molvik P., et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005, 7(3):497-508.
33. Vinik E.J., Hayes C., Oglesby A., Vinik A.I. Identification of factors in the nerve fiber specific norfolk quality of life (QOL-DN) inventory that reflect QOL and health status. ADA Annual meeting 2004, Abs no 1212-P.
34. Vileikyte L., Peyrot M., Bundy C., Rubin R.R., Leventhal H., Mora P., et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003, 26(9):2549-2555.
35. Vickrey B.G., Hays R.D., Beckstrand M. Development of a health-related quality of life measure for peripheral neuropathy. Neurorehabil Neural Repair 2000, 14(2):93-104.
36. McClimans L.M., Browne J. Choosing a patient-reported outcome measure. Theor Med Bioeth 2011, 32(1):47-60.
37. Thistead R.A., Klaff L., Schwartz S.L., Wymer J.P., Clligan N.W., Gerard G., et al. Dextromethorphan and Quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label dose escalation study. Clin Ther 2006, 28(10):1607-1618.
38. Kaye R., Thistead R.A., Hepner A., Shaibani A. Improved patient-centered outcomes with Dextromethorphan/Quinidine vs placebo in a phase iii, double blind, randomized placebo-controlled trial investigating painful diabetic peripheral neuropathy. Second international conference on neuropathic pain 2007, Abstract no P1498.
39. Vileikyte L., Leventhal H., Gonzalez J.J., Peyrot M., Rubia R.R., Ulbrecht J.S., et al. Diabetic peripheral neuropathy and depressive symptoms: the association revisited. Diabetes Care 2005, 28(10):2378-2383.
40. Kulzer B., Hermanns N., Stark S., Haak T. Quality of life in patients with diabetic neuropathy. ADA 67th scientific sessions 2007, Abstract No. 1966-P.
41. Hermanns N., Kulzer B., Stark S., Haak T. Screening for diabetic neuropathy using the neuroqol. ADA 67th scientific sessions 2007, Abstract No. 1965-P.
42. Vileikyte L., Peyrot M., Gonzalez J., Rubin R., Ulbrecht J., Leventhal H., et al. Longitudinal validation of the neuropathy and foot-ulcer specific quality of life instrument (NeuroQOL). Diabetes (New York) 2007, 56(Suppl. 1):307.
43. Lavery L.A., Murdoch D.P., Williams J., Lavery D.C. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care 2008, 31(2):316-321.
44. Vileikyte L., Shen B.J., Hardman M.J., Kirsner R.S., Boulton A.J.M., Schneiderman N. Emotional distress may impede diabetic foot ulcer healing through elevated levels of interleukin-6: preliminary findings. Diabetologia 2010.
45. Davies M., Brophy S., Williams R., Taylor A. Prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006, 29(7):1518-1522.
46. Dalal K., Maran B., Tripathi D.E., Mishra M.A. A randomized clinical trial on the effect of reflexology in the management of patients suffering from diabetic neuropathy diabetes technology and therapeutics. 4th International conference on advanced technologies and treatments for diabetes 2011.
47. Teixeira E., Reishtein J. The effect of mindfulness meditation on sleep for diabetic peripheral neuropathy. 24th Annual meeting of the associated professional sleep societies 2010.
48. Vinik A., Clinical Review: Use of antiepileptic Drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab 2005, 90(8):4936-4945.
49. Vinik E., Boyd A., Casellini C., Vinik A. Norfolk QOL-DN provides an outcome measure in clinical trials independent of traditional objective measures of nerve function. ADA 67th scientific sessions 2007, Abstract No. 0805-P.
50. Vinik E.J., Stansberry K.B., Doviak M.J., Sarah R., Vinik A. Norfolk quality of life (QOL) tool: scoring and reproducibility in healthy people. Diabetic controls and patients with neuropathy. ADA 63rd scientific sessions 2003.
51. Vinik E., Stansberry K.B., Vinik A. Neuropathy quality of life tool (Norfolk QOL-DN) in a large clinical trial: comparison with symptom scores (NSS) nerve impairment (NISS). Quantitative sensory (QST), autonomic (QAFFT) tests and electrophysiology. ADA 63rd scientific sessions 2003.
52. Vinik E.J., Stansbeny K.B., Oglesby A., Bastyr E., Vinjk A.I. Norfolk quality of life (QOL) tool: relationship between indices of QOL and specific nerve fiber symptoms and neurologic disabilities. Presented at international diabetes federation congress 2003.
53. Rice A.L., Vinik E., Barlow P.M., Ford-Molvic S.L., Vinik A. Topiramate treatment improves quality of life (QOL) and nerve function in patients with diabetic neuropathy. ADA 66th scientific sessions 2006.
54. Casselini C.M., Barlow P.M., Rice A.L., Casey M., Simmons K., Pittenger G., et al. A 6-month, randomized double-masked placebo-controlled study evaluating the effects of the protein kinase c-inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 2007, 30(4):896-902.
55. Currie C.J., Poole C.D., Woehl A., Morgan C.L., Cawley S., Rousculp M.D., et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006, 49(10):2272-2280.
56. Vinik E.J., Paulson J.F., Ford-Molvik S.L., Vinik A.I. German-translated norfolk quality of life (QOL-DN) identifies the same factors as the english version of the tool and discriminates different levels of neuropathy severity. J Diabetes Sci Technol 2008, 2(6):1075-1086.
57. Boyd A., Casselini C., Vinik E., Vinik A. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate Journal of diabetes science and technology. J Diabetes Sci Technol 2011, 5(3):714-722.